Levi & Korsinsky notifies investors that it has commenced an investigation into NeoGenomics, Inc. (NASDAQ: NEO) concerning potential violations of the federal securities laws.
On July 31, 2023, NeoGenomics' competitor, Natera, Inc., announced that it had sued NeoGenomics in federal court, alleging that the Company's cancer test, the RaDaR molecular residual disease assay, infringed Natera's patents. On December 27, 2023, Natera announced that the federal court had issued a preliminary injunction, effective immediately, barring NeoGenomics from making, using, selling, or promoting the RaDaR test, but that NeoGenomics may continue to offer RaDaR to existing patients and for clinical trials, studies, or projects already in process. The following day, NeoGenomics acknowledged the preliminary injunction, announcing that it would appeal the federal court's ruling. On this news, NeoGenomics' stock price fell $3.71 per share, or 18.1%, to close at $16.79 per share on December 28, 2023.
If you suffered a loss on your NeoGenomics securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





